4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butan-1-ol

Catalog No. :
ACBRVT682
CAS No. :
870765-38-1
Molecular Formula :
C14H20Cl2N2O
Molecular Weight :
303.23

IUPAC Name:4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-ol

4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butan-1-ol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butan-1-ol
IUPAC Name4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-ol
MDL No.MFCD12913403
Molecular FormulaC14H20Cl2N2O
Molecular Weight303.23
SMILESOCCCCN1CCN(C2=CC=CC(Cl)=C2Cl)CC1
InChI KeyTWCMWDBARFJWIY-UHFFFAOYSA-N
Synonym1-(2,3-dichlorophenyl)-4-(4-hydroxybutyl)piperazine;4-(2,3-Dichlorophenyl)-1-...;4-(2,3-Dichlorophenyl)-1-piperazinebutanol;4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-ol;Aripiprazole Hydroxybutylpiperazine Impurity;4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butanol HCl;1-Piperazinebutanol, 4-(2,3-dichlorophenyl)-;Aripiprazole Impurity 28(Hydrochloride)
CAS No.870765-38-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACBRVT682 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACDTQJ324 route compound structure diagram
    ACDTQJ3247447-41-8 In Stock
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACBRVT682 route product structure diagram
    ACBRVT682870765-38-1
Inquiry

2. ACBRVT682 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBRVT682 route product structure diagram
    ACBRVT682870765-38-1
Inquiry

Comments (0)